Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine – Eli Lilly and Company

Written by

admin

in

  1. Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine  Eli Lilly and Company
  2. Lilly weight-loss pill could be FDA-approved by year-end  Reuters
  3. Daily weight-loss pill raises hopes for fighting obesity  The Times
  4. Daily weight loss pill can help cut body weight by a fifth, trial shows  The Guardian
  5. Orforglipron: the age of ‘magic weight loss pill’ is almost upon us – and Britain may be first in line  British GQ

Continue Reading

More posts